Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333183 · ClinicalTrials.gov registry record · Phase 2
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
A Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07333183: Recruiting Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
NCT07333183 is a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension that is actively recruiting participants, run by Pulmovant. The registered enrollment target is 20 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07333183, a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, is actively recruiting participants, sponsored by Pulmovant.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Conditions Studied
Interventions
- DRUG inhaled mosliciguat
- DEVICE Dry Powder Inhaler
Study Locations (1)
Florida
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC - Kissimmee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-23 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT07333183 shows while recruiting
NCT07333183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which inhaled mosliciguat is the first listed.
NCT07333183 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07333183 about?
NCT07333183 is a clinical study titled "A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD". This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
What is the current status of trial NCT07333183?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-12-23. Estimated completion is 2028-01.
What conditions does trial NCT07333183 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pulmonary Hypertension, Vascular Diseases, Lung Diseases, Fibrosis.
What interventions are being tested in trial NCT07333183?
The interventions under investigation include: inhaled mosliciguat (DRUG), Dry Powder Inhaler (DEVICE).
Who is sponsoring clinical trial NCT07333183?
This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07333183 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07333183's enrollment target sits among peer trials
20 282nd of 300 higher than 14 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI